Company: LHI
Filing Date: 2025-05-23
Form Type: F-1
Source: 0001213900-25-046955
Chunk: 55

Company: Living Homeopathy International Ltd.
Filing Date: 2025-05-23
Form: F-1
Chunk 55
---
 completion of this offering, (b) in which we have total annual gross revenue of at least $1.235 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of Living Homeopathy’s Class A Ordinary Shares that is held by non-affiliates exceeds $700 million as of the prior fiscal year end, and (2) the date on which Living Homeopathy has issued more than $1.0 billion in non-convertible debt during the prior three-year period. An emerging growth company may take advantage of specified reduced reporting and other requirements that are otherwise applicable generally to public companies. These provisions include exemption from the auditor attestation requirement under Section 404 in the assessment of the emerging growth company’s internal control over financial reporting and permission to delay adopting new or revised accounting standards until such time as those standards apply to private companies.

Compliance with these rules and regulations increases Living Homeopathy’s legal and financial compliance costs and makes some corporate activities more time-consuming and costly. After Living Homeopathy is no longer an “emerging growth company,” or until five years following the completion of Living Homeopathy’s initial public offering, whichever is earlier, Living Homeopathy expects to incur significant expenses and devote substantial management effort toward ensuring compliance with the requirements of Section 404 and the other rules and regulations of the SEC. For example, as a public company, Living Homeopathy has been required to increase the number of independent directors and adopt policies regarding internal controls and disclosure controls and procedures. Living Homeopathy has incurred additional costs in obtaining director and officer liability insurance. In addition, Living Homeopathy incurs additional costs associated with its public company reporting requirements. It may also be more difficult for Living Homeopathy to find qualified persons to serve on its board of directors or as executive officers. Living Homeopathy is currently evaluating and monitoring developments with respect to these rules and regulations, and Living Homeopathy cannot predict or estimate with any degree of certainty the amount of additional costs we may incur or the timing of such costs.

Living Homeopathy’s board of directors may decline to register transfers of Class A Ordinary Shares in certain circumstances.

Except in connection with the settlement of trades, transactions or transfers of Class A Ordinary Shares entered into through the facilities of a stock exchange or automated quotation system on which our Class A Ordinary Shares are listed or traded from time to time, Living Homeopathy’s Board may, in its sole discretion, decline to register any transfer of any Class A Ordinary Share.

If Living Homeopathy’s directors refuse to